Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials. (2024). SKIN The Journal of Cutaneous Medicine, 8(4), s404. https://doi.org/10.25251/skin.8.supp.404